Biogen (NASDAQ: BIIB) reported third-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 6% decline in Q3 revenues to $3.38 billion, beating the Wall Street consensus. Earnings of $8.84 per share were also stronger than what analysts had anticipated.
BIIB shares were trading flat immediately following the announcement. The stock has slipped 9% since the beginning of this year.
Biogen also lowered its guidance for the full year, hurt by multiple Tecfidera generic entrants in the US.
Prior performance
Most Popular
BIIB Earnings: Biogen Q1 2024 adj. earnings rise despite lower revenues
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Wednesday reported an increase in adjusted profit for the first quarter of 2024, despite a decline in revenues. Total revenue declined 7% year-over-year to
Hasbro (HAS) Q1 2024 Earnings: Key financials and quarterly highlights
Hasbro, Inc. (NASDAQ: HAS) reported first quarter 2024 earnings results today. Revenues decreased 24% year-over-year to $757.3 million. Net earnings attributable to Hasbro, Inc. were $58.2 million, or $0.42 per
BA Earnings: Highlights of Boeing’s Q1 2024 financial results
The Boeing Company (NYSE: BA) on Wednesday announced financial results for the first quarter of 2024, reporting a narrower net loss, on an adjusted basis. Revenues dropped 8%. Core loss,
